According to numerous literature data, all of the metabolic pathways studied (glycolysis, glutaminolysis, fatty acid biosynthesis, and one-carbon metabolism), as well as mTOR and NMYC, are important and prospective drug targets in neuroblastoma [11,41,42,43,44]. This evidence concerns the gene MTOR and neuroblastoma.